On Tuesday, Truist Securities adjusted its outlook on Sutro Biopharma (NASDAQ:STRO), a company listed on NASDAQ under the ticker NASDAQ:STRO, by reducing its stock price target to $18 from the previous $25. Despite the price target reduction, the firm sustained its Buy rating on the biopharmaceutical company's stock.
Truist Securities cited three upcoming potential events within the next 12 months that could pivotally affect the company's shares or attract deal interest. These events include an update to the Luvelta and Bevacizumab combination treatment, initial data for Luvelta in treating lung cancer, and results from Part 1 of the ReFRαME study in ovarian cancer.
The adjustment in price target and outlook comes as a result of a comprehensive update of earnings, a reassessment of timelines and assumptions to more conservative yet still prudent figures, and the incorporation of new deal accounting into one refreshed financial model.
Truist Securities expressed continued optimism for Sutro Biopharma, despite the lower price target, stating that the new target of $18 is still the highest on Wall Street. The firm's stance remains positive on the company's prospects.
InvestingPro Insights
As Sutro Biopharma navigates a critical period with upcoming potential events that could significantly impact its stock, real-time data from InvestingPro provides a deeper look into the company's financial health and market performance.
With a market capitalization of $317.83 million, the company has demonstrated a remarkable revenue growth of 126.84% over the last twelve months as of Q4 2023. This growth is further underscored by an explosive quarterly revenue increase of 1217.44% in Q4 2023.
InvestingPro Tips suggest that while Sutro Biopharma holds more cash than debt, indicating a strong balance sheet, it is also quickly burning through cash. Analysts are anticipating a sales decline in the current year, and they do not expect the company to be profitable this year. However, the company has seen a significant return over the last week, with a 27.39% price total return, and a strong return over the last three months, at 16.52%.
These insights, particularly the company's quick cash burn and the anticipation of a sales decline, may be of interest to investors considering the optimistic outlook from Truist Securities. For those looking to delve deeper into Sutro Biopharma's financials and forecasts, InvestingPro offers additional tips and metrics. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and discover the wealth of information available, including 11 more InvestingPro Tips for Sutro Biopharma at: https://www.investing.com/pro/STRO.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.